Literature DB >> 7657300

Role of nitric oxide and prostacyclin in the control of renal perfusion in experimental cirrhosis.

J Ros1, J Clària, W Jiménez, M Bosch-Marcé, P Angeli, V Arroyo, F Rivera, J Rodés.   

Abstract

Nitric oxide (NO) and prostacyclin (PGI2) are two important modulators of renal function under normal conditions; however, little is known on their contributory role in cirrhosis with ascites. In this study, mean arterial pressure, renal hemodynamics, and sodium excretion were measured in 15 rats with cirrhosis and ascites and 16 control rats. Animals were studied in normal conditions, after inhibiting the synthesis of NO (N omega-nitro-L-arginine, 50 micrograms.kg-1.min-1) or prostaglandins (lysin acetylsalicylate, 15 mg.kg-1).min-1 and following the concomitant inhibition of both systems. Cirrhotic rats showed increased systemic pressure sensitivity and blunted renal vasoconstrictor response to nitric oxide inhibition as compared with control rats. As a consequence, the glomerular filtration rate increased in cirrhotic rats but not in control rats. In both groups of animals, NO inhibition was associated with significant increased urinary sodium and fractional sodium excretion. The only significant effect observed after prostaglandin biosynthesis inhibition was a decrease in renal plasma flow in cirrhotic rats. The concomitant inhibition of both systems reduced renal plasma flow and did not change glomerular filtration rate, with no differences between control and cirrhotic rats. Prostaglandin inhibition did not prevent the natriuretic effect of the NO inhibitor in both groups of animals. These results indicate that in experimental cirrhosis both NO and PGI2 play an important role in the maintenance of renal perfusion within normal limits.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7657300

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  12 in total

Review 1.  Renal dysfunction in cirrhosis: diagnosis, treatment and prevention.

Authors:  Elaine Yeung; Elaine Yong; Florence Wong
Journal:  MedGenMed       Date:  2004-12-02

Review 2.  Animal models of portal hypertension.

Authors:  Juan-G Abraldes; Marcos Pasarín; Juan-Carlos García-Pagán
Journal:  World J Gastroenterol       Date:  2006-11-07       Impact factor: 5.742

Review 3.  Terlipressin and hepatorenal syndrome: what is important for nephrologists and hepatologists.

Authors:  Ahmed A Magan; Atif A Khalil; Mohamed H Ahmed
Journal:  World J Gastroenterol       Date:  2010-11-07       Impact factor: 5.742

4.  Cyclooxygenase-1 derived prostaglandins are involved in the maintenance of renal function in rats with cirrhosis and ascites.

Authors:  Marta López-Parra; Joan Clària; Anna Planagumà; Esther Titos; Jaime L Masferrer; B Mark Woerner; Alane T Koki; Wladimiro Jiménez; Rosario Altuna; Vicente Arroyo; Francisca Rivera; Joan Rodés
Journal:  Br J Pharmacol       Date:  2002-02       Impact factor: 8.739

5.  Nitric oxide synthase (NOS) inhibition for one week improves renal sodium and water excretion in cirrhotic rats with ascites.

Authors:  P Y Martin; M Ohara; P Gines; D L Xu; J St John; M Niederberger; R W Schrier
Journal:  J Clin Invest       Date:  1998-01-01       Impact factor: 14.808

6.  Increased hepatic expression of nitric oxide synthase type II in cirrhotic rats.

Authors:  Hai Wang; Xiao-Ping Chen; Fa-Zu Qiu
Journal:  World J Gastroenterol       Date:  2004-07-01       Impact factor: 5.742

Review 7.  Kidneys in chronic liver diseases.

Authors:  Marek Hartleb; Krzysztof Gutkowski
Journal:  World J Gastroenterol       Date:  2012-06-28       Impact factor: 5.742

Review 8.  Acute Kidney Injury in Patients with Cirrhosis.

Authors:  Kirk B Russ; Todd M Stevens; Ashwani K Singal
Journal:  J Clin Transl Hepatol       Date:  2015-09-15

9.  Strain of experimental animals and modulation of nitric oxide pathway: their influence on development of renal failure in an experimental model of hepatorenal syndrome.

Authors:  Marek Saracyn; Janusz Patera; Janusz Kocik; Marek Brytan; Robert Zdanowski; Arkadiusz Lubas; Wojciech Kozłowski; Zofia Wańkowicz
Journal:  Arch Med Sci       Date:  2012-07-04       Impact factor: 3.318

Review 10.  Optimal management of hepatorenal syndrome in patients with cirrhosis.

Authors:  Paolo Angeli; Filippo Morando
Journal:  Hepat Med       Date:  2010-06-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.